




SAPIENZA
UNIVERSITÀ DI ROMA


Idiopathic Pulmonary Fibrosis: Pulmonary functional reprise by reinfusion of CRISPR-Cas9 edited alveolar stem cells AT2

Alice Amico, Edoardo Brandi, Marco D'Angelo





AIM: is it possible to recover IPF-lung functionality by patient derived edited AT2 cells infusion?







IPF-fibroblast




IPF- Mutation Primer design

Adapted from Zapparoli, G. V. et al. *BMC Cancer* (2013)




Adapted from Manolescu et al
D. Clin Interv Aging (2018)




Adapted from Yoshizaki K et al.
BMC Vet Res. 2021

The recruited IPF-patient shows both mutations of interest (I791V and M867V)



Patient derived fibroblast



Patient derived fibroblast

Target sequence:

AGAAATCATCCACCAAACGCAGG


LEFT ARM

ACAAGAAATCATCCACCAA




RIGHT ARM

CGCAGGAGCAGCCTAAA

Patient derived-fibroblasts was transfected using two lentiviral vectors to obtain two cell lines: **Cas 9** (edited and labeled) and **GFP** (labeled)








Adapted from Badakov, R. & Jazwińska, *Cytotechnology* (2006)




Adapted from Manolescu *et al* D. *Clin Interv Aging* (2018)

We observed proper integration for the lentiviral vectors and expression of carried genes





Adapted from Ohnuki M, Takahashi K. *Philos Trans R Soc Lond B Biol Sci.* 2015


mRNA transfection of IPF patient edited and labeled cells was used to obtain iPSC cell lines



Adapted from Garforth SJ, Wu YY, Prasad VR. *Biochem J.* 2006








A non-protein level dependent TERT functional recovery is showed by the Cas9 line






Adapted from Jacob A et al. *Cell Stem Cell*.

AT2 cell lines were obtained from iPSC lines through a 41 days-differentiation protocol



Each of the 4 differentiated lines showed expression of AT2 cells genes comparable to WT



Cas9 showed functional recovery:
AT2 cells staminal pool is conserved, while differentiation and proliferation to AT1 cells is recovered



TERT -/-

Bleomycin
low dose
→



IPF
model

Povedano, Juan M et al. - 2015







TERT -/-




WT

Povedano, Juan M et al. - 2015





We used TERT -/- mice treated with bleomycin as animal model for *in vivo* treatment






AT2 edited cells in both of the human and mice cell cultures showed an advantage compared to GFP, WT and IPF lines. Therefore, we believe AT2 cells to be effective in restoring AT2 cells pool *in vivo*.




After 10 days by the injection of Cas9 cells in the IPF mouse model a reprisal of the AT2 cells functionality is observed, as showed by the comparable to WT levels of the selected markers






The mixed population (AT1/AT2) is maintained *in vivo* 30 days after injection




Adapted from Cony, F. Get al. *Pesquisa Veterinária Brasileira* (2019)



After 30 days by the injection of Cas9 cells in IPF mice, a tissue regeneration and replacement of the fibrotic areas is showed when compared to untreated IPF mice. Furthermore, an increase of survival up to 15 Mo. is observed



Project Planning





Budget

Costs	Total Budget	Co-Funding	List of costs proposed for funding to the backer	Percentage of total proposed to the backer
Staff salary	0,00	0,00	Not permitted	0
Researchers' contracts	80.000,00	0,00	80.000,00	23,73887
Equipment (leasing-rent)	0,00	0,00	0,00	0
Supplies	140.000,00	0,00	140.000,00	41,54303
Model costs	60.000,00	0,00	60.000,00	17,80415
Subcontracts	0,00	0,00	0,00	0
Patients' costs	3.500,00	0,00	3.500,00	1,038576
IIT services and databases	0,00	0,00	0,00	0
Publication costs	4.000,00	0,00	4.000,00	1,186944
Conferences	3.500,00	0,00	3.500,00	1,038576
Travels	6.000,00	0,00	6.000,00	1,780415
Overheads	40.000,00	0,00	40.000,00	11,86944
Coordination costs	0,00	0,00	0,00	0
Total	337.000,00	0,00	337.000,00	100



Future perspectives

- Follow up after 30 days in terms of survival, safety and efficacy
- *In vivo* step in human
- Is it possible to cryoconserve patient derived edited cells in a AT2-state?
- Is there an alternative to intrapulmonary injection?
- Does this protocol properly work on other mutations or sporadic form of IPF?



Bibliography

- Zapparoli, G. V. *et al. BMC Cancer* (2013)
- Manolescu *et al D. Clin Interv Aging* (2018)
- Yoshizaki K *et al. BMC Vet Res.* 2021
- Badakov, R. & Jaźwińska, *Cytotechnology* (2006)
- Ohnuki M, Takahashi K. *Philos Trans R Soc Lond B Biol Sci.* 2015
- Garforth SJ, Wu YY, Prasad VR. *Biochem J.* 2006
- Povedano, Juan M *et al.* – 2015
- Cony, F. *Get al. Pesquisa Veterinária Brasileira* (2019)